Compare Mounjaro vs Wegovy: Which Prescription Suits You?
Online Prescription Access for Mounjaro vs Wegovy Weight Loss
When comparing Mounjaro vs Wegovy weight loss options, the convenience of online prescription access transforms how you begin treatment. Traditional GP appointments can involve weeks of waiting lists and potentially uncomfortable conversations about weight management. Our streamlined online service eliminates these barriers, allowing you to complete a comprehensive clinical assessment from home in just 3 minutes.
The assessment covers your medical history, current BMI, existing medications, and contraindications for both Mounjaro and Wegovy. Licensed UK prescribers review every case individually, ensuring you receive the most appropriate treatment option. This personalised approach means whether Wegovy's GLP-1 mechanism or Mounjaro's dual GIP and GLP-1 action is better suited to your circumstances, you'll receive expert guidance without the traditional healthcare system delays.
Mounjaro vs Wegovy Weight Loss: Pricing and Value Comparison
Understanding the cost implications when comparing Mounjaro vs Wegovy weight loss treatments helps inform your decision. Wegovy follows a structured dose escalation protocol, starting with 0.25mg at £79.99 for weeks 1-4, progressing to 0.5mg at £94.99 for weeks 5-8, then 1mg at £99.99 for weeks 9-12. The maintenance dose of 2.4mg costs £209.99 per pen from week 17 onwards. New customers benefit from code FIRST40 applied at checkout, whilst returning customers use code DOSE25.
Our bundle options provide supply convenience rather than pure savings, such as the Intro Duo (0.25mg and 0.5mg) for £169.99 or the Ultimate Stability Trio offering three months of 2.4mg maintenance supply for £649.99. This bundled approach ensures consistent treatment without the need for frequent reordering. Both Mounjaro and Wegovy are available through our prescription service, with your assigned prescriber helping determine which represents better value based on your individual treatment goals and medical profile.
Clinical Evidence: Mounjaro vs Wegovy Weight Loss Effectiveness
Clinical trial data provides valuable insight when evaluating Mounjaro vs Wegovy weight loss potential, though direct comparisons require careful interpretation due to different study designs and participant populations. Wegovy's evidence base centres on the STEP clinical trial programme, with STEP 1 demonstrating approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo, when used alongside diet and exercise modifications. The recent SELECT trial also showed a 20% reduction in major cardiovascular events amongst participants.
Mounjaro's tirzepatide mechanism combines GIP and GLP-1 receptor agonism, creating a dual approach to appetite regulation and glucose metabolism. However, comparing percentage weight loss figures between the medications directly can be misleading, as trial populations, endpoints, and methodologies varied significantly. Both treatments require prescription-only medicine status and must be used alongside a reduced-calorie diet and increased physical activity for optimal results.
How Wegovy Works for Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural fullness hormone your body produces after eating. This mechanism targets appetite centres in the brain, helping reduce food cravings and promoting earlier feelings of satiety during meals. The once-weekly injection delivered through the convenient FlexTouch pen system ensures consistent medication levels throughout the week. Unlike Ozempic, which is licensed specifically for type 2 diabetes management, Wegovy received MHRA approval specifically for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. The medication works most effectively when combined with lifestyle modifications, creating a comprehensive approach to long-term weight management rather than offering a quick-fix solution.
Streamlined Ordering Process for Both Medications
Accessing either Mounjaro or Wegovy through our online prescription service follows the same efficient pathway, removing traditional healthcare barriers. Your 3-minute clinical assessment captures essential medical information including current medications, previous weight loss attempts, and relevant health conditions that might influence prescriber decisions. Once submitted, our licensed UK prescribers review your case within 3 working days as standard, or within 24 hours if you select our express review option. Upon approval, your prescription-only medicine is dispatched via next-day delivery using specialist cold-chain transportation to maintain the medication's integrity. This temperature-controlled logistics network, operated through our GPhC registered pharmacy (#9012878), ensures your treatment arrives in optimal condition and ready for immediate use.
Storage and Practical Considerations: Mounjaro vs Wegovy
Practical storage requirements differ between Mounjaro and Wegovy, potentially influencing your choice depending on lifestyle factors. Wegovy offers superior storage flexibility, remaining stable at room temperature below 30°C for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both medications require initial refrigerated storage at 2-8°C until first use, but Wegovy's extended room temperature tolerance provides advantages for frequent travellers or those with unreliable refrigeration access. The FlexTouch pen delivery system used for Wegovy features dose confirmation windows and safety mechanisms that prevent accidental double-dosing. Dose escalation protocols must be followed precisely for both medications, starting with the lowest dose and gradually increasing according to prescriber guidance to minimise potential side effects whilst optimising therapeutic benefits.
Personalised Prescriber Guidance for Treatment Selection
The decision between Mounjaro vs Wegovy weight loss treatments benefits significantly from professional prescriber input, particularly through our comprehensive online assessment system. Your assigned prescriber considers factors beyond simple BMI calculations, including your medical history, current medications, previous treatment responses, and lifestyle requirements. This personalised approach ensures the selected medication aligns with your individual circumstances rather than following a one-size-fits-all protocol.
Our prescribers maintain detailed knowledge of both medications' mechanisms, contraindications, and optimal patient profiles, enabling informed recommendations based on current clinical evidence. Whether Wegovy's established GLP-1 pathway or Mounjaro's dual-action approach better suits your needs, you'll receive clear guidance on expected outcomes, potential side effects, and long-term treatment strategies. This expert oversight continues throughout your treatment journey, with ongoing prescription reviews ensuring sustained safety and effectiveness.
Start Your Online Prescription Journey Today
Beginning your Mounjaro vs Wegovy weight loss comparison with an actual prescription pathway transforms research into actionable treatment plans. Our 3-minute assessment provides immediate clarity on which medication suits your circumstances, whilst discount codes FIRST40 for new customers and DOSE25 for returning patients ensure competitive pricing from the outset. The combination of clinical expertise, regulatory compliance through our GPhC registration, and streamlined delivery logistics creates a comprehensive service designed around patient convenience. Both Wegovy and Mounjaro represent significant advances in prescription weight management, and your choice between them should be informed by professional medical guidance rather than marketing claims alone. Complete your clinical assessment today to discover which treatment option offers the most appropriate pathway toward your weight management goals, backed by ongoing prescriber support and assured pharmaceutical quality.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
